Compare Cytokinetics Inc (CYTK) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs VNET Group Inc — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while VNET Group Inc trades at $7.53 (market cap $2.13B). The key difference: Cytokinetics Inc is far larger — about 5.1× VNET Group Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | VNET | |
|---|---|---|
Market Cap | $10.78B | $2.13B |
Sector | Technology | Technology |
52-Week High | $87.26 | $14.03 |
52-Week Low | $34.31 | $6.29 |
Enterprise Value | $10.88B | $5.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
VNET trades at $7.33, up 4.56% in the last 24 hours, but technical indicators signal a bearish trend with RSI near overbought levels. The company reported a net loss of $256.77 million in 2025, with negative profit margins and ROE, though revenue grew to $9.95 billion. Recent news highlights strategic investor entry and AI-driven demand boosting wholesale data center growth, with Q2 2026 earnings due August 18, 2026.
The outlook remains mixed: analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt-to-asset ratio pose risks. Investment opportunity hinges on execution of capacity expansions and AI demand, while volatility from options trading and legal settlements adds uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
